• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jexpmedHomeThe Rockefeller University PressThis articleEditorsContactInstructions for AuthorsThis issue
J Exp Med. Mar 15, 2010; 207(3): 565–577.
PMCID: PMC2839148

CCR6 is expressed on an IL-10–producing, autoreactive memory T cell population with context-dependent regulatory function

Abstract

Interleukin (IL)-10 produced by regulatory T cell subsets is important for the prevention of autoimmunity and immunopathology, but little is known about the phenotype and function of IL-10–producing memory T cells. Human CD4+CCR6+ memory T cells contained comparable numbers of IL-17– and IL-10–producing cells, and CCR6 was induced under both Th17-promoting conditions and upon tolerogenic T cell priming with transforming growth factor (TGF)–β. In normal human spleens, the majority of CCR6+ memory T cells were in the close vicinity of CCR6+ myeloid dendritic cells (mDCs), and strikingly, some of them were secreting IL-10 in situ. Furthermore, CCR6+ memory T cells produced suppressive IL-10 but not IL-2 upon stimulation with autologous immature mDCs ex vivo, and secreted IL-10 efficiently in response to suboptimal T cell receptor (TCR) stimulation with anti-CD3 antibodies. However, optimal TCR stimulation of CCR6+ T cells induced expression of IL-2, interferon-γ, CCL20, and CD40L, and autoreactive CCR6+ T cell lines responded to various recall antigens. Notably, we isolated autoreactive CCR6+ T cell clones with context-dependent behavior that produced IL-10 with autologous mDCs alone, but that secreted IL-2 and proliferated upon stimulation with tetanus toxoid. We propose the novel concept that a population of memory T cells, which is fully equipped to participate in secondary immune responses upon recognition of a relevant recall antigen, contributes to the maintenance of tolerance under steady-state conditions.

IL-10 is an important immune-regulatory cytokine (Moore et al., 2001), and IL-10 produced by T cells is important for the prevention of autoimmune disease and immunopathology upon chronic infections (Groux et al., 1997; Asseman et al., 1999; Roers et al., 2004; Anderson et al., 2007; Jankovic et al., 2007; Couper et al., 2008). Two main subsets of IL-10–producing T cells with immune-regulatory functions have been described: “natural” and “adaptive” T reg cells (Bluestone and Abbas, 2003). Both subsets have been shown to prevent autoimmune diseases and limit immune responses (Groux et al., 1997; Roncarolo and Levings, 2000; Maloy and Powrie, 2001; Vieira et al., 2004), and lack IL-2–producing capacities (Groux et al., 1997; Sakaguchi, 2004; Vieira et al., 2004; Scheffold et al., 2005). They can be generated from naive T cells following different protocols of tolerogenic priming (Groux et al., 1997; Seddon and Mason, 1999; Jonuleit et al., 2000; Walker et al., 2003; Apostolou and von Boehmer, 2004), and TGF-β is required for IL-10 production from both subsets in vivo (Maynard et al., 2007). Natural T reg cells have been characterized in detail both in mice and humans. Thus, natural T reg cells can already mature in the thymus and express CD25, the high affinity receptor for IL-2, (Shevach, 2001; Sakaguchi, 2004), and the transcription factor FOXP3 (Sakaguchi, 2004). The maintenance and function of natural CD25+ T reg cells relies on IL-2 that is produced by activated Th cells (Scheffold et al., 2005), consistent with the autoimmune phenotype of IL-2–deficient mice. However, IL-2 also has some immunostimulatory effects, which might be induced at higher levels of IL-2 production (Scheffold et al., 2005), because it can promote memory T cell generation (Dooms et al., 2007) and autoimmunity (Waithman et al., 2008). Less is known about adaptive T reg cells because their phenotype and characteristics vary between different experimental settings. However, we have recently identified CD4+FOXP3 effector-like cells in human blood that coproduce IL-10 and IFN-γ and suppress T cell activation via IL-10 (Häringer et al., 2009). Notably, these Tr1-like cells are distinct from memory cells, because they are activated in vivo, have lost IL-7Rα expression, produce little IL-2, and do not respond to vaccination antigens.

The strength of TCR stimulation depends on the avidity of the TCR/peptide–MHC interaction and on engagement of co-stimulatory receptors, and is an important parameter of T cell activation to discriminate between tolerance and immunity (Lanzavecchia and Sallusto, 2002). In the thymus, developing T cells with a low affinity for self-MHC molecules are selected for survival (van den Boorn et al., 2006), whereas those with a higher affinity for self-peptides become CD25+ T reg cells (Jordan et al., 2001). In the periphery, low-level TCR stimulation of mature naive T cells by self-MHC is essential for their survival and antigen responsiveness in the mouse (Brocker, 1997; Stefanová et al., 2002). Importantly, this TCR “tickling” by self-MHC is also important for mouse CD4+ memory T cells, because they become nonfunctional upon transfer into MHC class II–deficient hosts (Kassiotis et al., 2002). However, suboptimal TCR stimulation in the absence of co-stimulation can also induce a state of unresponsiveness called anergy in T cells (Schwartz, 1997), or lead to a state of unfitness and abortive proliferation in both mouse and human T cells (Gett et al., 2003). The strength of TCR stimulation also regulates different functional responses, because clones derived from human CD8+ memory T cells have different stimulation thresholds for cytotoxicity, IFN-γ production, and proliferation (Valitutti et al., 1996). In the case of CD4+ T cells, it was shown that IL-2 and IL-10 are preferentially induced by different co-stimulatory receptors (Hutloff et al., 1999; Blair et al., 2000), but whether the secretion of these two key cytokines is differentially regulated by the strength of TCR stimulation has not been investigated.

CCR6 is a chemokine receptor expressed on B cells, a fraction of T cells, and immature DCs (Schutyser et al., 2003). The ligand of CCR6, CCL20, is widely expressed constitutively in lymphoid and nonlymphoid tissues and up-regulated upon inflammation, but the CCR6–CCL20 axis appears to be particularly important for migration of immune cells to the gut and the skin (Cook et al., 2000; Schutyser et al., 2003). Studies on CCR6-deficient mice indicated a nonredundant role for CCR6 in gut lymphoid tissue homeostasis (Cook et al., 2000; Varona et al., 2001). Furthermore, CCR6-deficient mice have altered CD4+ T cell responses, including reduced contact hypersensitivity and enhanced delayed type hypersensitivity responses (Lukacs et al., 2001; Varona et al., 2001, 2005). CCL20 and CCR6 are further involved in several autoimmune diseases including psoriasis (Homey et al., 2000), inflammatory bowel disease (Varona et al., 2003; Kaser et al., 2004), experimental autoimmune encephalomyelitis (Kleinewietfeld et al., 2005), and rheumatoid arthritis (Matsui et al., 2001; Ruth et al., 2003). Furthermore, we and others have shown that CCR6 is expressed on human Th17 cells (Acosta-Rodriguez et al., 2007; Annunziato et al., 2007).

In this paper, we show that CCR6+ human memory T cells have a low stimulation threshold for IL-10 production and, consequently, secrete IL-10 after suboptimal stimulation by autologous DCs ex vivo and in the spleen in situ. These autoreactive memory T cells are distinct from the effector-like cells with regulatory activity that we identified previously (Häringer et al., 2009). They produce IL-2 and IFN-γ, and proliferate after strong stimulation with recall antigens, suggesting that they can have a context-dependent function depending on the strength of TCR stimulation.

RESULTS

TGF-β promotes CCR6 expression on primed human CD4+ T cells

The chemokine receptor CCR6 is expressed on Th17 and T reg cells (Kleinewietfeld et al., 2005; Acosta-Rodriguez et al., 2007; Annunziato et al., 2007). We observed that TGF-β promoted CCR6 expression after naive (CD45RA+CCR7+CCR6CD25) human CD4+ T cell priming with anti-CD3 and anti-CD28 antibodies (Fig. 1 a) or allogenic DCs (not depicted). Naive T cells were labeled with CFSE for these experiments to exclude undivided cells from the analysis. TGF-β–dependent CCR6 expression was inhibited by the Th1- or Th2-polarizing cytokines IL-4 or IL-12 but not by IL-10. IL-4 was highly efficient in preventing CCR6 expression, because it completely prevented TGF-β–dependent CCR6 induction (in six different donors in independent experiments from 22 ± 12 to 2 ± 2%; P < 0.05), whereas IL-12 also reduced the mean CCR6 expression significantly but less efficiently (to 10 ± 4%). Consistent with previous results (Acosta-Rodriguez et al., 2007), the proinflammatory cytokines TNF, IL-1β, and IL-6 also promoted CCR6 expression and synergized with TGF-β, indicating that CCR6 can be induced under either tolerogenic or Th17-promoting conditions. In the absence of polarizing or proinflammatory cytokines, TGF-β promoted FOXP3 expression as expected (Fantini et al., 2004), but a fraction of CCR6+ cells remained FOXP3, showing that cells that acquire CCR6 upon tolerogenic priming do not necessarily become FOXP3+ T reg cells. Consistently, as shown in Fig. 1 b, CCR6 in human blood was found not only on the majority of FOXP3+ T reg cells but also on a large fraction of CD25FOXP3 memory cells, whereas phenotypic naive cells were largely CCR6. Virtually all (99%) CD25CCR6+ cells expressed the memory marker IL-7Rα, but they were heterogeneous for CCR7, integrin β7, and cutaneous lymphocyte-associated antigen (CLA), indicating that they contained central memory T, effector memory T, and gut- and skin-homing cells (Fig. 1 c). A similar heterogeneity was observed among CCR6 cells for all analyzed surface markers with the exception of the integrin αE subunit (also regulated by TGF-β; Hadley et al., 1997), which was selectively expressed on a small fraction of CCR6+ cells (Fig. 1 c). Collectively, these results suggest that CCR6 is expressed on antigen-experienced T cells that could have been primed under either tolerogenic or Th17-promoting conditions.

Figure 1.
CCR6 is induced by TGF-β and expressed on populations of CD25+ T reg cells and CD4+ memory T cells. (a) CFSE-labeled peripheral blood naive CD4+ T cells were stimulated with anti-CD3 and anti-CD28 antibodies for 4 d in the presence or absence ...

Low stimulation threshold for IL-10 production in CCR6+ memory T cells

Human memory T cells have different activation thresholds for the expression of activation-induced surface receptors. Thus, total memory cells could be efficiently activated by suboptimal stimulation with anti-CD3 antibodies to express the CD69 activation marker but required CD28 co-stimulation for the up-regulation of CD40L (Fig. 2 a). Also, the induction of cytokines had different stimulation thresholds. Thus, memory T cells secreted IL-10 efficiently at late time points with anti-CD3 antibodies alone, whereas IL-2 secretion and optimal IFN-γ production occurred earlier and required CD28 co-stimulation (Fig. 2 b).

Figure 2.
Ex vivo cytokine production of CCR6+ and CCR6 memory T cells after weak or strong TCR stimulation. (a) Up-regulation of CD69 and CD40L after stimulation of total antigen-experienced Th cells (CD45RACD25) with anti-CD3 alone ...

We previously showed that CCR6 is expressed on human blood Th17 cells but not on Th2 cells, whereas IL-2– and IFN-γ–producing cells are present among both CCR6+ and CCR6 T cells (not depicted; Acosta-Rodriguez et al., 2007). We investigated the IL-10–producing capacities of CCR6+ and CCR6 memory T cells in response to anti-CD3 antibodies in the absence or presence of CD28 co-stimulation. Because IL-7R is a memory cell marker and IL-7R cells are effector-like cells with high IL-10–producing capacities (Häringer et al., 2009), we also purified CCR6+ and CCR6 memory T cell populations according to IL-7R expression. Interestingly, although variable fractions of both CCR6+ and CCR6 memory T cells produced IL-10 in response to anti-CD3 in the presence of CD28 co-stimulation, only CCR6+ T cells secreted IL-10 efficiently upon stimulation with anti-CD3 antibodies alone (4.3 ± 2.6 vs. 0.7 ± 0.4%; P < 0.05; Fig. 2 c). Similar results were obtained by analyzing supernatants of stimulated cells by ELISA (unpublished data). The fraction of CCR6+ T cells producing IL-10 with anti-CD3 was relatively small, but it was similar to the fraction of Th17 cells (4.6 ± 2.8% of IL-17A+ cells upon CD28 co-stimulation; Fig. 2 c). Conversely, a major fraction of CCR6+ T cells possessed CCL20-producing capacities, including not only virtually all Th17 cells, as expected, but also many IL-10–secreting cells (Fig. 2 c) that lack IL-17–producing capacities (not depicted; Häringer et al., 2009). Thus, unlike CCR6 memory T cells, CCR6+ cells could attract other CCR6+ cells via CCL20 and secrete IL-10 efficiently upon weak TCR stimulation. Conversely, both CCR6+ and CCR6 memory cells produce CD40L, IL-2, IL-10, and IFN-γ after optimal activation.

CCR6+ T cells produce suppressive IL-10 upon contact with autologous DCs

We then analyzed whether memory T cell populations differed in autoreactivity, which we defined as the capacity to proliferate or secrete cytokines in response to autologous DCs. We used circulating DCs isolated ex vivo, because in healthy subjects they could present self-antigens as well as physiologically relevant innocuous foreign antigens that they are exposed to in the steady state. Allogenic DCs were used in parallel as a positive control. CFSE-labeled CCR6+ and CCR6 T cells proliferated vigorously with allogenic DCs, as expected, but weakly (CCR6+) or not at all (CCR6) with autologous DCs (Fig. 3 a). However, CCR6+ but not CCR6 memory T cells proliferated vigorously with autologous DCs when neutralizing anti–IL-10 antibodies were added, whereas an isotype-matched control antibody had no effect (not depicted). CCR6+ memory T cell proliferation with autologous DCs shared several features with conventional antigenic proliferation, as it was inhibited by neutralizing antibodies to MHC class II and by natural T reg cells (unpublished data). CD25+ T reg cells could also proliferate with autologous DCs but required the addition of exogenous IL-2, whereas IL-10 neutralization had no effect (unpublished data).

Figure 3.
CCR6+ memory T cells proliferate with autologous DCs upon IL-10 neutralization. (a) Purified CCR6+ and CCR6 T cells were incubated with ex vivo–isolated autologous or allogenic mDCs in the presence or absence of neutralizing anti–IL-10 ...

To understand whether DCs or T cells produced the suppressive IL-10 in autologous cultures, we resorted the two cell types after co-culture and measured the IL-10 mRNA. Notably, CCR6+ T cells constitutively expressed IL-10 mRNA, and IL-10 was superinduced in CCR6+ T cells upon co-culture with DCs (Fig. 3 b). Conversely, IL-10 mRNA was neither detected in myeloid DCs (mDCs) ex vivo nor induced after co-culture with CCR6+ T cells, showing that the suppressive IL-10 was derived exclusively from CCR6+ T cells. Consistent with the mRNA expression, supernatants from autologous CCR6+ T cell–DC co-cultures contained considerable amounts of IL-10 but little IL-2 (Fig. 3 c), consistent with the notion that autologous DCs provide only weak stimulation for autologous T cells in the absence of exogenous antigens. Conversely, both IL-10 and IL-2 were detected in allogenic co-cultures. Notably, although comparable amounts of IL-10 were produced in autologous and allogenic cultures, IL-10 neutralization had no clear effect on alloreactive T cell proliferation (Fig. 3 a). Thus, the capacity of CCR6+ T cells to suppress T cell proliferation via IL-10 was limited to conditions of weak TCR stimulation and limited IL-2 availability. Consistently, addition of exogenous IL-2 to autologous cultures induced vigorous CCR6+ T cell proliferation in the absence of IL-10 neutralization, and CCR6 T cells also proliferated under this condition, but to a lower extent (unpublished data). In summary, these findings indicate that autologous DCs provide a suboptimal TCR stimulation of CCR6+ T cells, which is sufficient for IL-10 production that, in a negative feedback loop, inhibits autoreactive T cell proliferation.

Immature mDCs activate autoreactive CCR6+ T cells efficiently

The extent of the CCR6+ autoreactive T cell proliferation with different subsets of autologous APCs was associated with the well-established capacities of these APC subsets to activate CD4+ T cells. Thus, autoreactive proliferation was highest with mDCs, lower with plasmacytoid DCs (pDCs), and very low or absent with monocytes (unpublished data). Surprisingly, however, mDCs were less stimulatory for autoreactive T cells after LPS-induced maturation, although mature mDCs more potently activated allogenic T cells, as expected (Fig. 4 a). Interestingly, the reduced capacity of mDCs to activate autologous T cells upon LPS maturation was associated with the down-regulation of the transcription factor AIRE (Fig. 4 b). Previous work has shown that AIRE allows presentation of tissue-restricted antigens by specialized APC subsets predominantly in the thymus (Kyewski and Klein, 2006) but also in the periphery (Ramsey et al., 2006). Notably, human blood mDCs, but not pDCs or monocytes, expressed CCR6 ex vivo (Fig. 4 c), and they down-regulated CCR6 upon maturation with LPS (not depicted). In summary, immature mDCs that express CCR6 and AIRE activate autoreactive CCR6+ memory T cells most efficiently.

Figure 4.
Immature mDCs most efficiently induce autoreactive T cell proliferation. (a) Purified, CFSE-labeled CCR6+ memory T cells were cultured with autologous or allogenic immature or LPS-matured mDCs in the presence of neutralizing anti–IL-10 antibodies, ...

To understand whether CCR6+ T cells could be activated by immature mDCs in vivo, we analyzed normal human spleen sections for localization of CCR6+ T cells and mDCs. As shown in Fig. 5, CCR6+ T cells (yellow arrows) were present in T cell zones of the human spleen, and the majority of them were in close proximity to CD11c+ DCs, i.e., mDCs (inset, CCR6 CD11c; and Table I). Strikingly, we could identify IL-10–producing T cells in the human spleen in situ. Scattered IL-10+ cells were detected within the periarteriolar T cell areas, and these cells were also located close to CD11c+ DCs (Fig. 5, inset, IL-10 CD11c). A considerable fraction of the IL-10+ T cells coexpressed CCR6 (Fig. 5, bottom right, yellow), but they were largely negative for FOXP3 (inset, FOXP3 IL-10; and Table I). These results are consistent with the view that immature mDCs activate autoreactive CCR6+ memory T cells in the steady state to produce IL-10.

Table I.
Number of T cells interacting with mDCs, expressing CCR6, FOXP3, or IL-10 in human spleen sections
Figure 5.
CCR6+ T cells colocalize with CD11c+ DCs and produce IL-10 in the human spleen. (top) Spleen sections showing anti-CCR6–labeled CCR6+ cells (red) in the anti-CD3–stained (green) T cell areas and B cell follicles with a proportion of CCR6/CD3 ...

Context-dependent cytokine profile of CCR6+ tetanus-specific T cell clones

We next analyzed specificities of CCR6+ and CCR6 memory T cell populations to self- and recall antigens (Fig. 6 a). Responses to the melanocyte self-antigen MelanA were detected exclusively among CCR6+ T cells in six out of eight donors, whereas one donor did not respond and another one with a very high response among CCR6+ cells had a lower response among CCR6 cells, confirming that autoreactive T cells express CCR6 in healthy subjects (14 vs. 3% proliferating cells; P < 0.05; Fig. 6 b). Conversely, in four vitiligo autoimmune patients that have lost tolerance to melanocyte-derived antigens, MelanA-specific cells were mostly or exclusively CCR6 (2 vs. 14%; Fig. 6 b). Consistent with previous results, tetanus-specific cells were detectable in both CCR6+ and CCR6 populations (Acosta-Rodriguez et al., 2007). We next investigated whether autoreactive and recall-specific T cells exclusively represented two distinct populations within CCR6+ T cells, or if CCR6+ T cells contained recall antigen–specific cells that cross reacted with antigens presented by autologous DCs. CCR6+ T cells that had divided extensively with autologous DCs in the presence of anti–IL-10 were isolated and analyzed for responsiveness to recall antigens. A variable fraction of these autoreactive cells in all donors analyzed responded to various recall antigens, including tetanus toxoid (TT) and other nonpersistent vaccination antigens (Fig. 6 c and Table II). Clones derived from single autoreactive cells were then analyzed for proliferation and cytokine production after stimulation with autologous APCs in the absence or presence of TT. Several autoreactive CCR6+ clones from two different donors were obtained that proliferated vigorously with TT and produced high amounts of IL-2, IL-10, and IFN-γ (Fig. 7, a and b), but not IL-17 (not depicted). Notably, when cells from the same tetanus-specific clones were stimulated with autologous mDCs alone, they produced IL-10 but not IL-2 and proliferated poorly and only upon IL-10 neutralization (Fig. 7 b). Conversely, two CCR6 tetanus-specific clones from the same donors did not respond to mDCs alone (Fig. 7, a and b). Finally, autoreactive, tetanus-specific CCR6+ T cell clones had different activation thresholds for IL-2 and IL-10 production, as expected. Thus, they produced IL-10 only with anti-CD3 alone (unpublished data) or after CD28 co-stimulation at low anti-CD3 concentrations (1–2 ng/ml; Fig. 7 c). Conversely, they produced IL-2 together with IL-10 after CD28 co-stimulation at higher anti-CD3 concentration (>4 ng/ml). We conclude that autoreactive CCR6+ memory T cells have a context-dependent behavior, because cells derived from the same memory precursor proliferate and secrete IL-2, IFN-γ, and IL-10 upon strong stimulation with recall antigens, whereas they produce mainly IL-10 upon weak stimulation with autologous DCs.

Table II.
Antigen specificities of autoreactive T cell lines
Figure 6.
CCR6+ T cells respond to self- and recall antigens in healthy donors. (a) Sorted CFSE-labeled CCR6+ and CCR6 T cells from healthy individuals were cultured with autologous monocytes with or without MelanA or TT. CFSE profiles of CD3+CD14 ...
Figure 7.
Autoreactive CCR6+ T cell clones produce IL-2 with recall antigens. Clones were generated by expanding single cells from CCR6+ autoreactive T cell lines or from CCR6 TT-specific control lines and screened for tetanus specificity by [3H]thymidine ...

DISCUSSION

The presence of IL-10–producing memory cells in humans has been known for a long time, but their function and phenotype has remained unclear. In this study, we showed that human CCR6+ memory T cells secrete IL-10 efficiently in response to suboptimal TCR stimulation, whereas they produce immunostimulatory cytokines at higher levels of stimulation. These different activation thresholds allow autoreactive CCR6+ memory T cells to secrete suppressive IL-10 in response to autologous DCs, whereas they produce IFN-γ, IL-2, and CD40L upon strong activation, as can be provided by a recall antigen. Thus, memory T cells that cross react with antigens presented by autologous mDCs could have a context-dependent function and inhibit autoreactivity in the steady state, but contribute to recall responses upon infections or vaccinations.

IL-10 production by T cells inhibits autoimmunity and immunopathology, and the induction of IL-10–producing capacities in mouse Th cells requires TGF-β (Maynard et al., 2007). We found that tolerogenic priming with TGF-β induced CCR6 on naive T cells in vitro and that the polarizing cytokines IL-12 and in particular IL-4 inhibited CCR6 expression. CCR6 was also induced by proinflammatory cytokines and is expressed on human blood Th17 cells (Acosta-Rodriguez et al., 2007), raising the question of whether the IL-10–producing CCR6+ memory cells might belong to the Th17 lineage. However, we recently showed that IL-17 and IL-10 coproducing cells in human blood are largely absent from the memory compartment (Häringer et al., 2009). Moreover, the autoreactive, tetanus-specific clones analyzed did not produce IL-17, consistent with the view that IL-10–producing CCR6+ memory cells are distinct from Th17 cells. Nevertheless, a considerable fraction of IL-10–producing CCR6+ memory T cells possessed CCL20-producing capacities and could thus attract other CCR6+ cells, including immature mDCs (Vanbervliet et al., 2002). Although CCL20 production was low in response to weak TCR stimulation, these low amounts might be nevertheless physiologically relevant. Consistently, in situ analysis revealed that CCR6+ T cells in normal human spleens were enriched in the vicinity of CCR6+ mDCs. Obviously, we cannot exclude that chemokines other than CCL20 are responsible for this colocalization; in particular, CCR4 ligands are known to be constitutively expressed by immature mDCs, and a fraction of IL-10–producing CCR6+ T cells coexpresses CCR4 (unpublished data). Importantly, we could show that some of the CCR6+ T cells in the spleen were actively secreting IL-10 and interacted with mDCs, but were mostly FOXP3. Mouse T cells with IL-10–producing capacities have been previously detected at low frequency in the spleen of mice and are enriched in the gut (Maynard et al., 2007). In humans, IL-10–producing T cells have been previously visualized in the gut (Uhlig et al., 2006), but to our knowledge this is the first study that characterizes IL-10–producing T cells in the human spleen in situ. Collectively, the in situ findings are consistent with the view that autoreactive CCR6+ memory T cells are activated by mDCs to secrete IL-10 under steady-state conditions. Moreover, autologous immature mDCs specifically activated CCR6+ memory T cells to produce suppressive IL-10 ex vivo. These circulating mDCs were isolated ex vivo, because in contrast to in vitro–generated DCs, they present physiologically relevant self- and innocuous foreign antigens. Immature mDCs expressed AIRE and down-regulated this transcription factor upon maturation with LPS, consistent with the view that immature DCs are tolerogenic and might be able to present tissue-restricted self-antigens (Steinman and Nussenzweig, 2002; Kyewski and Klein, 2006). Consistently, in some donors the T cells that had proliferated upon contact with immature mDCs responded to the self-antigen MelanA, which is also expressed in AIRE+ medullary thymic epithelial cells. It should be noted that the peptides that activate CCR6+ T cells in the steady state are not necessarily derived from self-antigens but might also be derived from innocuous foreign antigens to which normal individuals are continuously exposed. Finally, inhibitory cytokines secreted upon DC maturation could also reduce the proliferation of autologous T cells.

CCR6+ memory T cells were IL-7Rα+ and possessed both IL-2– and IL-10–producing capacities, and are thus different from previously described professional T reg cell subsets (Groux et al., 1997; Sakaguchi, 2004; Vieira et al., 2004; Scheffold et al., 2005; Häringer et al., 2009). It was previously reported that IL-2 and IL-10 are differentially regulated by the co-stimulatory receptors inducible T cell co-stimulator, CD28, and CD40L (Hutloff et al., 1999; Blair et al., 2000). We found that in human memory T cells, IL-10 was efficiently induced by low-level stimulation with anti-CD3 in the absence of CD28 co-stimulation. We believe that IL-10 production in response to suboptimal stimulation is physiologically relevant, because mDCs, which are poorly stimulatory for autologous T cells in the absence of foreign antigens as a consequence of thymic selection, induced IL-10 quite efficiently. Conversely, secretion of IFN-γ and especially of IL-2 as well as expression of CD40L required strong activation that could be provided with anti-CD3/CD28 co-stimulation or allogenic DCs. Importantly, we found that different activation thresholds for IL-10 and IL-2 were also present in clones derived from single autoreactive CCR6+ memory T cells. In particular, different cytokine profiles and proliferative responses were induced in these clones with antigens associated with steady-state conditions (i.e., ex vivo–isolated mDCs) and recall responses (i.e., TT). Thus, the different cytokine profiles detected after weak or strong stimulation of polyclonal memory T cell populations do not simply reflect cellular heterogeneity, but single memory cells have the potential to secrete different cytokines depending on the conditions of antigenic stimulation and thus exert different functions. It should be noted that the autoreactive memory clones we isolated are distinct from conventional autoreactive T cell clones that are fully activated by autologous APCs alone (Kitani et al., 2000), but they might be related to the ones that spontaneously grow out from PBMCs and react with multiple self-antigens (Cai and Hafler, 2007).

Our data raise the question of why the immune system harbors context-dependent regulatory memory T cells when it already possesses different types of professional T reg cells. In the thymus and the periphery, T cells are selected to recognize self-antigens with low affinity, and highly autoreactive naive T cells that escape negative selection are probably immediately deleted or converted to professional T reg cell cells in the periphery. Conversely, many slightly autoreactive T cells that are not sufficiently activated by immature DCs in the naive state might be suboptimally activated after differentiation to memory cells, because memory cells are characterized by a lower activation threshold (Pihlgren et al., 1996). In this scenario, newly generated memory T cells that are activated by immature DCs could be educated by TGF-β to acquire CCR6 and IL-10–producing capacities. The CCR6+ memory T cells could then be activated in the steady state and secrete low levels of IL-10 to inhibit autoreactive T cells in a paracrine manner, or increase their own activation threshold by an autocrine-negative feedback loop. This strategy would allow the immune system to maintain a broad TCR repertoire for pathogen recognition and at the same time limit the intrinsic risk of autoimmunity caused by T cell memory.

MATERIALS AND METHODS

Cell culture.

CD4+ T cells were isolated from PBMCs from healthy donors as described previously (Rivino et al., 2004). Human primary cell protocols were approved by the Federal Office of Public Health. PBMCs from vitiligo patients were obtained from C. Mainetti (San Giovanni Hospital, Bellinzona, Switzerland). T cell populations were purified by cell sorting based on expression of CD45RA, CD25, and CCR6 to a purity of >95% and labeled with CFSE. Antibodies used to determine T cell phenotype were anti-CXCR5 and anti-CCR7 (both purchased from R&D Systems), anti-CLA, anti–IL-7Ra, and anti–integrin β7 and αE (Beckman Coulter). Cells were cultured in complete RPMI 1640 medium containing 5% pooled human serum or, in some experiments, autologous plasma. Monocytes were purified with anti-CD14 beads (Miltenyi Biotec), whereas circulating pDCs and mDCs were isolated by cell sorting after enrichment for BDCA-2–PE+ and CD1c-FITC+ cells, respectively, with ant-FITC and anti-PE beads (Miltenyi Biotec), excluding CD19+ B cells and CD14+ monocytes with allophycocyanin-labeled antibodies. 2 × 104 CFSE-labeled CD4+ T cells were cultured with DCs in 96 round-bottom wells at a 5:1 ratio. Cloning of cells proliferating with autologous DCs was performed by plating 0.5 cells/well in 96 U-bottom wells in the presence of 106 cells/ml of irradiated allogeneic PBMCs, 1 µg/ml PHA (Sigma-Aldrich), and 1,000 U/ml IL-2. Antigen specificity of purified CD4+ T cell populations was assessed by co-culturing CFSE-labeled T cells with irradiated autologous monocytes at a 1:1 ratio in the presence or absence of the recombinant antigens MelanA (1 µg/ml; Prospec), TT (1 µg/ml; Novartis), influenza hemagglutinin Texas (Prospec), purified protein derivate (Statens Institute), or a lysate of CMV-infected cells (provided by G. Gerna, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy). On day 7, CFSE dilution was assessed by flow cytometry. In some experiments, proliferating cells were briefly restimulated in the presence of bredfeldin A (Sigma-Aldrich) with autologous monocytes in the absence or presence of various antigens to control antigen specificity by intracellular cytokine staining. Recombinant cytokines were used at the concentrations of 25 ng/ml (TGF-β was purchased from R&D Systems; IL-2, IL-10, IL-4, and IL-12 were purchased from BD), whereas neutralizing antibodies to IL-10 or MHC class II (BD) were used at the concentration of 10 µg/ml.

Cytokine production.

Cytokine production of purified T cell populations was assessed after stimulation of 25 × 103 cells in 100 µl for 24 h in wells coated with optimal amounts (2 µg/ml) of anti-CD3 alone or with an optimal combination of anti-CD3 plus anti-CD28 antibodies (0.1 and 6 µg/ml, respectively; both purchased from BD). Cell-culture supernatants were assessed for the presence of cytokines by ELISA and were analyzed with the Softmax program. Intracellular cytokines were detected after stimulating cells for 6 h in the presence of 10 µg/ml brefeldin A for the last 2 h of culture. Cells were fixed with 4% formaldehyde and permeabilized with saponin, and nonspecific binding was blocked with 10% FCS. Cells were stained with labeled antibodies for IL-10, IL-2, IFN-γ, TNF (all purchased from BD), IL-17A (purchased from eBioscience), or CCL20 (purchased from R&D Systems), washed, and analyzed by flow cytometry. Intracellular FOXP3 was detected with a staining kit by following the manufacturer’s instructions (eBioscience).

mRNA extraction and quantitative RT-PCR.

IL-10 and AIRE mRNA induction was analyzed by real-time quantitative RT-PCR. After co-culture, DCs and T cells were reseparated by cell sorting and total RNA was extracted using the TRIzol method (Invitrogen) according to the manufacturer’s instructions. cDNA synthesis was performed by RT-PCR by using random hexamers and a Moloney murine leukemia virus transcriptase kit (Agilent Technologies). IL-10 transcripts were quantified by real-time quantitative PCR on a sequence detector (ABI PRISM 7700; Applied Biosystems) with predesigned gene expression assays and reagents (TaqMan; Applied Biosystems). For each sample, the mRNA abundance was normalized to the amount of 18S rRNA and is expressed in arbitrary units.

Immunohistochemistry.

2–3-µm-thick sections of formalin-fixed, paraffin-embedded tissue from well-preserved splenectomy specimens after trauma were cut, deparaffinized, and subjected to a heat-induced epitope retrieval step. Slides were rinsed in cool running water and washed in Tris-buffered saline, pH 7.4, before incubation with primary rabbit anti-CD3 (clone N1580; 1:10; Dako), mouse anti-CD3 (clone LN10; 1:100; Novocastra), mouse anti-CCR6 (clone 53103; 1:20; R&D Systems), mouse anti-CD11c (clone 5D11; 1:20; Novocastra), rabbit anti–IL-10 (clone 500-P20; 1:100; PeproTech), or rat anti-FOXP3 (clone PCH101; 1:100; eBioscience) antibodies for 30 min. For detection, donkey anti–rabbit (Dianova), rabbit anti–rat (Dako), or donkey anti–mouse (Dianova) secondary antibodies were used, followed by the streptavidinPO kit (Dako), the streptavidinAP kit (Dako), the EnvisionPO kit (Dako), or the alkaline phosphatase anti–alkaline phosphatase method. Alkaline phosphatase was revealed by Fast Red as chromogen, and peroxidase was developed with a highly sensitive diaminobenzidine chromogenic substrate for 10 min. Negative controls were performed by omitting the primary antibodies. For anti–IL-10 labeling, EBV-positive classical Hodgkin lymphoma served as a positive control (Herbst et al., 1996). Additional negative controls were performed by blocking the IL-10 antibody with recombinant human IL-10 (Sigma-Aldrich). For double immunofluorescence labeling, sections were incubated with rabbit anti-CD3 or mouse anti-CCR6 antibody followed by Alexa Fluor 488–conjugated anti–rabbit or anti–mouse antibody (1:100; Invitrogen), washed three times in PBS, and incubated with mouse anti-CCR6 or rabbit anti–IL-10 followed by Alexa Fluor 555–conjugated anti–mouse or anti–rabbit antibody (1:100; Invitrogen). Nuclei were counterstained with DAPI (1:1,500; Roche), and slides were mounted in Fluoromount-G (SouthernBiotech). Images were acquired using a fluorescence microscope (AxioImager Z1) equipped with a charge-coupled device camera (AxioCam MRm) and processed with AxioVision software (all purchased from Carl Zeiss, Inc.).

Statistics.

Statistical significance was calculated with a two-tailed Student’s t test. P < 0.05 was regarded as statistically significant.

Acknowledgments

We thank E. Berg and S. Spieckermann for excellent technical assistance with the immunohistochemical and immunofluorescence stainings, and S. Wirths and A. Hauser for critical reading and discussion.

This work was supported by the Swiss National Foundation (grant 31000A0-104168) and the Deutsche Forschungsgemeinschaft (Junior Group grants SFB650 TPN01 and SFB650 Z3).

The authors have no conflicting financial interests.

Footnotes

Abbreviations used:

CLA
cutaneous lymphocyte-associated antigen
mDC
myeloid DC
pDC
plasmacytoid DC
TT
tetanus toxoid

References

  • Acosta-Rodriguez E.V., Rivino L., Geginat J., Jarrossay D., Gattorno M., Lanzavecchia A., Sallusto F., Napolitani G. 2007. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 8:639–646 10.1038/ni1467 [PubMed] [Cross Ref]
  • Anderson C.F., Oukka M., Kuchroo V.J., Sacks D. 2007. CD4+CD25Foxp3 Th1 cells are the source of IL-10–mediated immune suppression in chronic cutaneous leishmaniasis. J. Exp. Med. 204:285–297 10.1084/jem.20061886 [PMC free article] [PubMed] [Cross Ref]
  • Annunziato F., Cosmi L., Santarlasci V., Maggi L., Liotta F., Mazzinghi B., Parente E., Filì L., Ferri S., Frosali F., et al. 2007. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204:1849–1861 10.1084/jem.20070663 [PMC free article] [PubMed] [Cross Ref]
  • Apostolou I., von Boehmer H. 2004. In vivo instruction of suppressor commitment in naive T cells. J. Exp. Med. 199:1401–1408 10.1084/jem.20040249 [PMC free article] [PubMed] [Cross Ref]
  • Asseman C., Mauze S., Leach M.W., Coffman R.L., Powrie F. 1999. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 190:995–1004 10.1084/jem.190.7.995 [PMC free article] [PubMed] [Cross Ref]
  • Blair P.J., Riley J.L., Harlan D.M., Abe R., Tadaki D.K., Hoffmann S.C., White L., Francomano T., Perfetto S.J., Kirk A.D., June C.H. 2000. CD40 ligand (CD154) triggers a short-term CD4+ T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. J. Exp. Med. 191:651–660 10.1084/jem.191.4.651 [PMC free article] [PubMed] [Cross Ref]
  • Bluestone J.A., Abbas A.K. 2003. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3:253–257 10.1038/nri1032 [PubMed] [Cross Ref]
  • Brocker T. 1997. Survival of mature CD4 T lymphocytes is dependent on major histocompatibility complex class II–expressing dendritic cells. J. Exp. Med. 186:1223–1232 10.1084/jem.186.8.1223 [PMC free article] [PubMed] [Cross Ref]
  • Cai G., Hafler D.A. 2007. Multispecific responses by T cells expanded by endogenous self-peptide/MHC complexes. Eur. J. Immunol. 37:602–612 10.1002/eji.200636787 [PubMed] [Cross Ref]
  • Cook D.N., Prosser D.M., Forster R., Zhang J., Kuklin N.A., Abbondanzo S.J., Niu X.D., Chen S.C., Manfra D.J., Wiekowski M.T., et al. 2000. CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity. 12:495–503 10.1016/S1074-7613(00)80201-0 [PubMed] [Cross Ref]
  • Couper K.N., Blount D.G., Wilson M.S., Hafalla J.C., Belkaid Y., Kamanaka M., Flavell R.A., de Souza J.B., Riley E.M. 2008. IL-10 from CD4CD25Foxp3CD127 adaptive regulatory T cells modulates parasite clearance and pathology during malaria infection. PLoS Pathog. 4:e1000004 10.1371/journal.ppat.1000004 [PMC free article] [PubMed] [Cross Ref]
  • Dooms H., Wolslegel K., Lin P., Abbas A.K. 2007. Interleukin-2 enhances CD4+ T cell memory by promoting the generation of IL-7Rα–expressing cells. J. Exp. Med. 204:547–557 10.1084/jem.20062381 [PMC free article] [PubMed] [Cross Ref]
  • Fantini M.C., Becker C., Monteleone G., Pallone F., Galle P.R., Neurath M.F. 2004. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25− T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol. 172:5149–5153 [PubMed]
  • Gett A.V., Sallusto F., Lanzavecchia A., Geginat J. 2003. T cell fitness determined by signal strength. Nat. Immunol. 4:355–360 10.1038/ni908 [PubMed] [Cross Ref]
  • Groux H., O’Garra A., Bigler M., Rouleau M., Antonenko S., de Vries J.E., Roncarolo M.G. 1997. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 389:737–742 10.1038/39614 [PubMed] [Cross Ref]
  • Hadley G.A., Bartlett S.T., Via C.S., Rostapshova E.A., Moainie S. 1997. The epithelial cell-specific integrin, CD103 (alpha E integrin), defines a novel subset of alloreactive CD8+ CTL. J. Immunol. 159:3748–3756 [PubMed]
  • Häringer B., Lozza L., Steckel B., Geginat J. 2009. Identification and characterization of IL-10/IFN-γ–producing effector-like T cells with regulatory function in human blood. J. Exp. Med. 206:1009–1017 10.1084/jem.20082238 [PMC free article] [PubMed] [Cross Ref]
  • Herbst H., Foss H.D., Samol J., Araujo I., Klotzbach H., Krause H., Agathanggelou A., Niedobitek G., Stein H. 1996. Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin’s disease. Blood. 87:2918–2929 [PubMed]
  • Homey B., Dieu-Nosjean M.C., Wiesenborn A., Massacrier C., Pin J.J., Oldham E., Catron D., Buchanan M.E., Müller A., deWaal Malefyt R., et al. 2000. Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J. Immunol. 164:6621–6632 [PubMed]
  • Hutloff A., Dittrich A.M., Beier K.C., Eljaschewitsch B., Kraft R., Anagnostopoulos I., Kroczek R.A. 1999. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature. 397:263–266 10.1038/16717 [PubMed] [Cross Ref]
  • Jankovic D., Kullberg M.C., Feng C.G., Goldszmid R.S., Collazo C.M., Wilson M., Wynn T.A., Kamanaka M., Flavell R.A., Sher A. 2007. Conventional T-bet+Foxp3 Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J. Exp. Med. 204:273–283 10.1084/jem.20062175 [PMC free article] [PubMed] [Cross Ref]
  • Jonuleit H., Schmitt E., Schuler G., Knop J., Enk A.H. 2000. Induction of interleukin 10–producing, nonproliferating CD4+ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192:1213–1222 10.1084/jem.192.9.1213 [PMC free article] [PubMed] [Cross Ref]
  • Jordan M.S., Boesteanu A., Reed A.J., Petrone A.L., Holenbeck A.E., Lerman M.A., Naji A., Caton A.J. 2001. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat. Immunol. 2:301–306 10.1038/86302 [PubMed] [Cross Ref]
  • Kaser A., Ludwiczek O., Holzmann S., Moschen A.R., Weiss G., Enrich B., Graziadei I., Dunzendorfer S., Wiedermann C.J., Mürzl E., et al. 2004. Increased expression of CCL20 in human inflammatory bowel disease. J. Clin. Immunol. 24:74–85 10.1023/B:JOCI.0000018066.46279.6b [PubMed] [Cross Ref]
  • Kassiotis G., Garcia S., Simpson E., Stockinger B. 2002. Impairment of immunological memory in the absence of MHC despite survival of memory T cells. Nat. Immunol. 3:244–250 10.1038/ni766 [PubMed] [Cross Ref]
  • Kitani A., Chua K., Nakamura K., Strober W. 2000. Activated self-MHC-reactive T cells have the cytokine phenotype of Th3/T regulatory cell 1 T cells. J. Immunol. 165:691–702 [PubMed]
  • Kleinewietfeld M., Puentes F., Borsellino G., Battistini L., Rötzschke O., Falk K. 2005. CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. Blood. 105:2877–2886 10.1182/blood-2004-07-2505 [PubMed] [Cross Ref]
  • Kyewski B., Klein L. 2006. A central role for central tolerance. Annu. Rev. Immunol. 24:571–606 10.1146/annurev.immunol.23.021704.115601 [PubMed] [Cross Ref]
  • Lanzavecchia A., Sallusto F. 2002. Progressive differentiation and selection of the fittest in the immune response. Nat. Rev. Immunol. 2:982–987 10.1038/nri959 [PubMed] [Cross Ref]
  • Lukacs N.W., Prosser D.M., Wiekowski M., Lira S.A., Cook D.N. 2001. Requirement for the chemokine receptor CCR6 in allergic pulmonary inflammation. J. Exp. Med. 194:551–555 10.1084/jem.194.4.551 [PMC free article] [PubMed] [Cross Ref]
  • Maloy K.J., Powrie F. 2001. Regulatory T cells in the control of immune pathology. Nat. Immunol. 2:816–822 10.1038/ni0901-816 [PubMed] [Cross Ref]
  • Matsui T., Akahoshi T., Namai R., Hashimoto A., Kurihara Y., Rana M., Nishimura A., Endo H., Kitasato H., Kawai S., et al. 2001. Selective recruitment of CCR6-expressing cells by increased production of MIP-3 alpha in rheumatoid arthritis. Clin. Exp. Immunol. 125:155–161 10.1046/j.1365-2249.2001.01542.x [PMC free article] [PubMed] [Cross Ref]
  • Maynard C.L., Harrington L.E., Janowski K.M., Oliver J.R., Zindl C.L., Rudensky A.Y., Weaver C.T. 2007. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3− precursor cells in the absence of interleukin 10. Nat. Immunol. 8:931–941 10.1038/ni1504 [PubMed] [Cross Ref]
  • Moore K.W., de Waal Malefyt R., Coffman R.L., O’Garra A. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:683–765 10.1146/annurev.immunol.19.1.683 [PubMed] [Cross Ref]
  • Pihlgren M., Dubois P.M., Tomkowiak M., Sjögren T., Marvel J. 1996. Resting memory CD8+ T cells are hyperreactive to antigenic challenge in vitro. J. Exp. Med. 184:2141–2151 10.1084/jem.184.6.2141 [PMC free article] [PubMed] [Cross Ref]
  • Ramsey C., Hässler S., Marits P., Kämpe O., Surh C.D., Peltonen L., Winqvist O. 2006. Increased antigen presenting cell-mediated T cell activation in mice and patients without the autoimmune regulator. Eur. J. Immunol. 36:305–317 10.1002/eji.200535240 [PubMed] [Cross Ref]
  • Rivino L., Messi M., Jarrossay D., Lanzavecchia A., Sallusto F., Geginat J. 2004. Chemokine receptor expression identifies pre–T helper (Th)1, pre–Th2, and nonpolarized cells among human CD4+ central memory T cells. J. Exp. Med. 200:725–735 10.1084/jem.20040774 [PMC free article] [PubMed] [Cross Ref]
  • Roers A., Siewe L., Strittmatter E., Deckert M., Schlüter D., Stenzel W., Gruber A.D., Krieg T., Rajewsky K., Müller W. 2004. T cell–specific inactivation of the interleukin 10 gene in mice results in enhanced T cell responses but normal innate responses to lipopolysaccharide or skin irritation. J. Exp. Med. 200:1289–1297 10.1084/jem.20041789 [PMC free article] [PubMed] [Cross Ref]
  • Roncarolo M.G., Levings M.K. 2000. The role of different subsets of T regulatory cells in controlling autoimmunity. Curr. Opin. Immunol. 12:676–683 10.1016/S0952-7915(00)00162-X [PubMed] [Cross Ref]
  • Ruth J.H., Shahrara S., Park C.C., Morel J.C., Kumar P., Qin S., Koch A.E. 2003. Role of macrophage inflammatory protein-3alpha and its ligand CCR6 in rheumatoid arthritis. Lab. Invest. 83:579–588 [PubMed]
  • Sakaguchi S. 2004. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22:531–562 10.1146/annurev.immunol.21.120601.141122 [PubMed] [Cross Ref]
  • Scheffold A., Hühn J., Höfer T. 2005. Regulation of CD4+CD25+ regulatory T cell activity: it takes (IL-)two to tango. Eur. J. Immunol. 35:1336–1341 10.1002/eji.200425887 [PubMed] [Cross Ref]
  • Schutyser E., Struyf S., Van Damme J. 2003. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 14:409–426 10.1016/S1359-6101(03)00049-2 [PubMed] [Cross Ref]
  • Schwartz R.H. 1997. T cell clonal anergy. Curr. Opin. Immunol. 9:351–357 10.1016/S0952-7915(97)80081-7 [PubMed] [Cross Ref]
  • Seddon B., Mason D. 1999. Peripheral autoantigen induces regulatory T cells that prevent autoimmunity. J. Exp. Med. 189:877–882 10.1084/jem.189.5.877 [PMC free article] [PubMed] [Cross Ref]
  • Shevach E.M. 2001. Certified professionals: CD4+CD25+ suppressor T cells. J. Exp. Med. 193:F41–F46 10.1084/jem.193.11.F41 [PMC free article] [PubMed] [Cross Ref]
  • Stefanová I., Dorfman J.R., Germain R.N. 2002. Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes. Nature. 420:429–434 10.1038/nature01146 [PubMed] [Cross Ref]
  • Steinman R.M., Nussenzweig M.C. 2002. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl. Acad. Sci. USA. 99:351–358 10.1073/pnas.231606698 [PMC free article] [PubMed] [Cross Ref]
  • Uhlig H.H., Coombes J., Mottet C., Izcue A., Thompson C., Fanger A., Tannapfel A., Fontenot J.D., Ramsdell F., Powrie F. 2006. Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. J. Immunol. 177:5852–5860 [PubMed]
  • Valitutti S., Müller S., Dessing M., Lanzavecchia A. 1996. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J. Exp. Med. 183:1917–1921 10.1084/jem.183.4.1917 [PMC free article] [PubMed] [Cross Ref]
  • Vanbervliet B., Homey B., Durand I., Massacrier C., Aït-Yahia S., de Bouteiller O., Vicari A., Caux C. 2002. Sequential involvement of CCR2 and CCR6 ligands for immature dendritic cell recruitment: possible role at inflamed epithelial surfaces. Eur. J. Immunol. 32:231–242 10.1002/1521-4141(200201)32:1<231::AID-IMMU231>3.0.CO;2-8 [PubMed] [Cross Ref]
  • van den Boorn J.G., Le Poole I.C., Luiten R.M. 2006. T-cell avidity and tuning: the flexible connection between tolerance and autoimmunity. Int. Rev. Immunol. 25:235–258 10.1080/08830180600743081 [PMC free article] [PubMed] [Cross Ref]
  • Varona R., Villares R., Carramolino L., Goya I., Zaballos A., Gutiérrez J., Torres M., Martínez-A C., Márquez G. 2001. CCR6-deficient mice have impaired leukocyte homeostasis and altered contact hypersensitivity and delayed-type hypersensitivity responses. J. Clin. Invest. 107:R37–R45 10.1172/JCI11297 [PMC free article] [PubMed] [Cross Ref]
  • Varona R., Cadenas V., Flores J., Martínez-A C., Márquez G. 2003. CCR6 has a non-redundant role in the development of inflammatory bowel disease. Eur. J. Immunol. 33:2937–2946 10.1002/eji.200324347 [PubMed] [Cross Ref]
  • Varona R., Cadenas V., Gómez L., Martínez-A C., Márquez G. 2005. CCR6 regulates CD4+ T-cell-mediated acute graft-versus-host disease responses. Blood. 106:18–26 10.1182/blood-2004-08-2996 [PubMed] [Cross Ref]
  • Vieira P.L., Christensen J.R., Minaee S., O’Neill E.J., Barrat F.J., Boonstra A., Barthlott T., Stockinger B., Wraith D.C., O’Garra A. 2004. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J. Immunol. 172:5986–5993 [PubMed]
  • Waithman J., Gebhardt T., Davey G.M., Heath W.R., Carbone F.R. 2008. Cutting edge: enhanced IL-2 signaling can convert self-specific T cell response from tolerance to autoimmunity. J. Immunol. 180:5789–5793 [PubMed]
  • Walker M.R., Kasprowicz D.J., Gersuk V.H., Benard A., Van Landeghen M., Buckner J.H., Ziegler S.F. 2003. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25− T cells. J. Clin. Invest. 112:1437–1443 [PMC free article] [PubMed]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...